Meeting
2023 ASCO Genitourinary Cancers Symposium
A phase II trial modifying metabolic syndrome and cardiovascular risk for patients with prostate cancer on ADT using a risk factor modification program and continuous Fitbit monitoring (ProTrio).
Authors
Andrew Warren Hahn
University of Texas MD Anderson Cancer Center, Houston, TX
Andrew Warren Hahn , Rebecca Slack Tidwell , Whittney Thoman , Amer Abdulla , Efstratios Koutroumpakis , Ana Aparicio , Sumit Kumar Subudhi , Bilal Ahmed Siddiqui , Patrick Glen Pilié , Amado J. Zurita , Paul Gettys Corn , Andrew Leonard Laccetti , Bagi RP Jana , Karen Basen-Engquist , Christopher Logothetis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Clinical Trial Registration Number
NCT05054296
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS273)
DOI
10.1200/JCO.2023.41.6_suppl.TPS273
Abstract #
TPS273
Poster Bd #
P15
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial.
First Author: Junlong Zhuang
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase II trial of ArtemiCoffee for men with biochemical recurrence of prostate cancer after local therapy.
First Author: Zin Myint
Poster
2023 ASCO Annual Meeting
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang
Poster
2023 ASCO Annual Meeting
Exercise to enhance cardiovascular health among Black patients with prostate cancer with androgen deprivation therapy: The POWER trial.
First Author: Dong-Woo Kang